SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Lifesciences informs about press release

07 Jun 2022 Evaluate

Zydus Lifesciences has informed that it enclosed a copy of press release dated June 7, 2022 titled ‘Zydus Lifesciences receives final approval from USFDA for Adapalene and Benzoyl Peroxide Topical Gel’.

The above information is a part of company’s filings submitted to BSE.

Zydus Lifesciences Share Price

927.65 -1.20 (-0.13%)
22-Apr-2026 10:29 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1657.70
Dr. Reddys Lab 1213.25
Cipla 1227.75
Zydus Lifesciences 927.65
Lupin 2305.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×